Galectin Therapeutics Inc
GALT
Company Profile
Business description
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Contact
4960 Peachtree Industrial Boulevard
Suite 240
NorcrossGA30071
USAT: +1 678 620-3186
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
9
Stocks News & Analysis
stocks
Cheap ASX share pays a heavy price for NRL rights
Growth has slowed amid increased competition for viewers and content.
stocks
The World Cup stock you’ve never heard of
This ASX stock is kicking goals at the FIFA World Cup.
stocks
Chart of the Week: Can WiseTech shares finally bounce back?
Market concerns over governance and AI fears have left shares trading well below the fair value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,003.70 | 34.90 | 0.39% |
| CAC 40 | 8,338.97 | 12.35 | 0.15% |
| DAX 40 | 25,067.09 | 51.18 | -0.20% |
| Dow JONES (US) | 52,637.01 | 149.60 | 0.29% |
| FTSE 100 | 10,497.29 | 24.84 | 0.24% |
| HKSE | 24,175.12 | 144.94 | 0.60% |
| NASDAQ | 26,281.61 | 74.72 | 0.29% |
| Nikkei 225 | 68,557.73 | 813.88 | 1.20% |
| NZX 50 Index | 13,785.67 | 120.49 | 0.88% |
| S&P 500 | 7,575.39 | 31.75 | 0.42% |
| S&P/ASX 200 | 8,806.00 | 38.20 | 0.44% |
| SSE Composite Index | 3,996.16 | 40.43 | -1.00% |